# 35Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/35pharma

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.35pharma.com/
- Total disclosed funding: $53M
- Latest round: Series C (Nov 26, 2024)
- Investors on record: 10

## About

Based in Quebec, Canada, 35Pharma Inc., a.k.a. 35Pharma operates as a clinical-stage biopharmaceutical company that specializes in creating biologics to address critical health issues, particularly those related to the TGF-beta superfamily. In February 2026, GlaxoSmithKline Plc, agreed to acquire 35Pharma Inc. from Columbia Threadneedle, Deep Track Capital, Frazier Life Sciences Management, Lp, Janus Henderson Investors, Logos Capital, Marshall Wace, Paradigm BioCapital, Surveyor Capital, VenBio, and Vivo Capital for USD 950 million.

35Pharma’s primary product offerings include highly potent ligand traps designed to selectively neutralize pathological activins and growth differentiation factors (GDFs), with key candidates such as HS135 for pulmonary hypertension and HS235 for cardiometabolic diseases and obesity. These products are created through a rigorous process that combines advanced protein engineering with a deep understanding of TGF-beta structure-function relationships, ensuring optimal efficacy. The company's research and development efforts are primarily conducted in their state-of-the-art facilities in Montreal, Canada.

35Pharma's revenue model is centered around the development and commercialization of its biologics, specifically targeting partnerships with healthcare providers and pharmaceutical companies to facilitate market entry and distribution. Transactions typically occur through strategic alliances and collaborations with larger pharmaceutical firms, as well as participation in clinical trials and regulatory agreements.

The acquisition aims to provide GlaxoSmithKline Plc HS235 inclusion within the Respiratory, Immunology and Inflammation portfolio.

## Funding rounds

- Series C, Nov 26, 2024, $53M — Vivo Capital, Marshall Wace, Columbia Threadneedle, VenBio, Janus Henderson Investors, Surveyor Capital, Logos Capital, Paradigm BioCapital, Deep Track Capital, Frazier Life Sciences Management, Lp

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series C
- Columbia Threadneedle — Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series C
- Janus Henderson Investors — Series C
- Surveyor Capital — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C
- Paradigm BioCapital — Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C
- Frazier Life Sciences Management, Lp — Series C